Effect of an Optimized Treatment With Insulin on Platelet Reactivity After Discharge in Patients With an Acute Coronary Syndrome and Hyperglycemia

被引:4
|
作者
Vivas, David [1 ]
Garcia-Rubira, Juan C. [1 ]
Bernardo, Esther [1 ]
Angiolillo, Dominick J. [1 ]
Martin, Patricia [2 ]
Calle, Alfonso [2 ]
Nunez-Gil, Ivan [1 ]
Macaya, Carlos [1 ]
Fernandez-Ortiz, Antonio [1 ]
机构
[1] Hosp Clin San Carlos, Inst Cardiovasc, Madrid 28040, Spain
[2] Hosp Clin San Carlos, Serv Endocrinol, Madrid 28040, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2014年 / 67卷 / 01期
关键词
Platelets; Acute coronary syndrome; Diabetes mellitus; ACUTE MYOCARDIAL-INFARCTION; TYPE-2; DIABETES-MELLITUS; GLUCOSE CONTROL; FUNCTION PROFILES; STRESS HYPERGLYCEMIA; GLYCEMIC CONTROL; THERAPY; CLOPIDOGREL; DISEASE; RISK;
D O I
10.1016/j.rec.2013.05.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: Intensive glucose control with insulin in patients with an acute coronary syndrome reduces platelet reactivity during hospitalization, compared to conventional control. However, the effect of strict, long-term glucose control on platelet reactivity in these patients remains uncertain. Methods: This is a prospective, randomized trial evaluating the effects of optimized glucose control (target glucose, 80-120 mg/dL) with insulin, compared with conventional control (target glucose, <180 mg/dL), on platelet reactivity after hospital discharge in patients with an acute coronary syndrome and hyperglycemia. The primary endpoint was assessment of platelet aggregation after stimulation with adenosine diphosphate 20 mu M at 12-month follow-up. Results: One hundred four patients were randomized to optimized management (n=53) or conventional management (n=51). There were no differences between groups in baseline characteristics or platelet function. After 12 months of follow-up, blood glucose levels were significantly lower in the optimized treatment group (104 vs 119 mg/dL; P<.001). However, platelet aggregation following adenosine diphosphate 20 mu M stimulation showed no differences between the groups (54.2% [14.3%] vs 55.1% [18.3%] respectively; P=.81). There were no significant differences for other platelet function tests. Conclusions: Long-term optimized glucose control with insulin in patients with an acute coronary syndrome did not result in a reduction in platelet reactivity compared to conventional control. (C) 2013 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S. L. All rights reserved.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 50 条
  • [41] Increased platelet reactivity in patients given Orbofiban after an acute coronary syndrome:: An OPUS-TIMI 16 substudy
    Holmes, MB
    Sobel, BE
    Cannon, CP
    Schneider, DJ
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (04): : 491 - 493
  • [42] CLOPIDOGREL TREATMENT AFTER CORONARY STENTING IN ACUTE CORONARY SYNDROME PATIENTS
    Nasir, Hira
    Khawar, Shanaza
    Hasan, Wazir Muhammad
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (12): : 16132 - 16134
  • [43] Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes
    Verdoia, Monica
    Sartori, Chiara
    Pergolini, Patrizia
    Nardin, Matteo
    Rolla, Roberta
    Barbieri, Lucia
    Schaffer, Alon
    Marino, Paolo
    Bellomo, Giorgio
    Suryapranata, Harry
    De Luca, Giuseppe
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (04) : 663 - 670
  • [44] Flow Cytometric Assessment of Changes in Platelet Reactivity after Acute Coronary Syndrome: A Systematic Review
    Pedersen, Oliver Buchhave
    Pasalic, Leonardo
    Nissen, Peter H.
    Grove, Erik Lerkevang
    Kristensen, Steen Dalby
    Hvas, Anne-Mette
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (05): : 542 - 551
  • [45] Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes
    Monica Verdoia
    Chiara Sartori
    Patrizia Pergolini
    Matteo Nardin
    Roberta Rolla
    Lucia Barbieri
    Alon Schaffer
    Paolo Marino
    Giorgio Bellomo
    Harry Suryapranata
    Giuseppe De Luca
    Journal of Thrombosis and Thrombolysis, 2016, 41 : 663 - 670
  • [46] Increased platelet reactivity in the initial 14 days after an acute coronary syndrome is not attenuated by orbofiban
    Holmes, MB
    Sobel, BE
    Schneider, DJ
    CIRCULATION, 1999, 100 (18) : 431 - 431
  • [47] Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention
    Song, Kai
    Jin, Xuan
    Kim, Moo-Hyun
    Li, Jia-Xin
    Jin, Cai-De
    Yuan, Song-Lin
    Song, Zhao-Yan
    Jin, En-Ze
    Lee, Kwang-Min
    Lim, Kyung-Hee
    Cho, Young-Rak
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)
  • [48] HIGH ON-TREATMENT PLATELET REACTIVITY: RISK FACTORS AND 3-YEARS OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Jakl, M.
    Sevcik, R.
    Vojacek, J.
    Fatorova, I.
    Horacek, J.
    Pudil, R.
    HAEMATOLOGICA, 2012, 97 : 191 - 191
  • [49] A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy
    Fabbri, Alessia
    Marcucci, Rossella
    Gori, Anna Maria
    Giusti, Betti
    Paniccia, Rita
    Balzi, Daniela
    Barchielli, Alessandro
    Valente, Serafina
    Giglioli, Cristina
    Abbate, Rosanna
    Gensini, Gian Franco
    THROMBOSIS RESEARCH, 2015, 136 (03) : 613 - 619
  • [50] NTEGRIN αIIBβ3 AS POTENTIAL BIOMARKER OF HIGH ON-TREATMENT PLATELET REACTIVITY TO CLOPIDOGREL IN PATIENTS WITH AN ACUTE CORONARY SYNDROME
    Gkourogianni, A.
    Tsoumani, M.
    Ntallas, I.
    Tsoukatos, D.
    Goudevenos, I.
    Tselepis, A.
    ATHEROSCLEROSIS, 2016, 252 : E25 - E25